Based on previous research on TLR agonists as vaccine adjuvants for anti-cancer therapies, Singh et al., found BC mice exposed to TLR4 and LPS had a better outcome than TLR4- or microbial-deficient mice [139]. Here, TLR4 is linked to cancer.